Safety and Efficacy Study of A0001 in Subjects With Friedreich's Ataxia

Completed · Phase 2 · Has a placebo group

Conditions studied: Friedreich's Ataxia

In brief

This is a Phase 2a double-blind, placebo-controlled study with two dose levels of A0001 given twice daily for 28 days. Potential subjects will be screened first to determine eligibility, after which they will be randomized to receive either a high dose of A0001, a low dose of A0001 or placebo for 28 days. Eligible subjects will return within 21 days of screening for the baseline visit and randomization to one of three potential treatments. The subjects will be required to take 3 capsules of study medication in the morning with a morning meal and 3 capsules of study medication at night with an evening meal for 28 days. Additional visits to the clinic are planned for Day 14 and Day 28, at which time a number of clinical and biochemical assessments will be done.

Key facts

Study ID

NCT01035671

Run by

Penwest Pharmaceuticals Co.

People needed

42

Starts

2009-12-01

Expected to finish

2011-03-01

Last updated by the study team

2011-04-22

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Individuals with genetically confirmed Friedreich's Ataxia (GAA or point mutation)
• Impaired Glucose Tolerance, measured by Oral GTT

You may not qualify if…

• Overt Diabetes Mellitus
• Presence of clinically significant cardiovascular disease

Where it is running

• The Children's Hospital of Philadelphia — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.